Ruxolitinib Versus Best Available Therapy in Patients With Glucocorticoid-Refractory Chronic Graft-Vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [1] Ruxolitinib (RUX) vs Best Available Therapy (BAT) in patients (pts) with Glucocorticoid-Refractory chronic Graft-vs-Host Disease (cGVHD): Primary findings from the phase 3, randomized REACH3 study
    Zeiser, R.
    Polverelli, N.
    Ram, R.
    Hashmi, S.
    Chakraverty, R.
    Langmuir, P.
    Hollaender, N.
    Gowda, M.
    Stefanelli, T.
    Lee, S. J.
    Teshima, T.
    Locatelli, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 65 - 66
  • [2] Ruxolitinib vs Best Available Therapy in Patients With Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 6 - 8
  • [3] Biomarker analysis in patients with steroid-refractory/dependent chronic graft-vs-host disease treated with ruxolitinib or best available therapy in the randomized phase 3 REACH3 study
    Locatelli, F.
    Zeiser, R.
    Teshima, T.
    Prahallad, A.
    Sinclair, K.
    Stefanelli, T.
    Lee, S. J.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 41 - 42
  • [4] Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study
    Zeiser, Robert
    Polverelli, Nicola
    Ram, Ron
    Hashmi, Shahrukh K.
    Chakraverty, Ronjon
    Flowers, Mary E. D.
    Dawkins, Fitzroy
    Hollaender, Norbert
    Gowda, Maanasa
    Stefanelli, Tommaso
    Lee, Stephanie J.
    Teshima, Takanori
    Locatelli, Franco
    BLOOD, 2020, 136
  • [5] Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial
    Locatelli, Franco
    Polverelli, Nicola
    Ram, Ron
    Hashmi, Shahrukh K.
    Chakraverty, Ronjon
    Middeke, Jan Moritz
    Musso, Maurizio
    Giebel, Sebastian
    Uzay, Ant
    Ayuk, Francis Ayuketang
    Zuckerman, Tsila
    Fukushima, Kentaro
    Vallejo, Juan Carlos
    Pidala, Joseph
    Hamad, Nada
    Moiseev, Ivan
    Bonifazi, Francesca
    Apte, Shashikant
    Langmuir, Peter
    Hollaender, Norbert
    Gowda, Maanasa
    Stefanelli, Tommaso
    Lee, Stephanie J.
    Zeiser, Robert
    Teshima, Takanori
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 74 - 76
  • [6] Biomarker and Safety Analyses of Patients With Steroid-Refractory Acute Graft-Vs-Host Disease Treated With Ruxolitinib or Best Available Therapy in the Randomized, Phase 3 REACH2 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 10 - 12
  • [7] Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study
    Zeiser, Robert
    Xue, Zhenyi
    Bhatt, Valkal
    Galvin, John
    Locatelli, Franco
    BLOOD, 2022, 140 : 10507 - 10508
  • [8] Safety analysis of Ruxolitinib (RUX) vs Best Available Therapy (BAT) in patients (pts) with Steroid-Refractory (SR) acute Graft-vs-Host Disease (aGVHD) in the randomized phase 3 REACH2 study
    von Bubnoff, N.
    Butler, J.
    Wagner, E.
    Forcade, E.
    Sanz, J.
    Russo, D.
    Grillo, G.
    Zuckerman, T.
    Bozdag, Civriz S.
    Ayuk, F.
    Stoelzel, F.
    Yoon, S-S
    Garcia-Gutierrez, V
    Ritchie, D.
    Bulabois, C-E
    Rubio, M-T
    Xu, J.
    Morando, J.
    Mahuzier, B.
    Chandraiah, Mahadevaiah S.
    Socie, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 230 - 231
  • [9] Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study
    Von Bubnoff, Nikolas
    Butler, Jason P.
    Wagner, Eva Maria
    Forcade, Edouard
    Caballer, Jaime Sanz
    Russo, Domenico
    Grillo, Giovanni
    Zuckerman, Tsila
    Bozdag, Sinem Civriz
    Ayuk, Francis A.
    Stoelzel, Friedrich
    Yoon, Sung-Soo
    Gutierrez, Jose Valentin Garcia
    Ritchie, David
    Bulabois, Claude-Eric
    Rubio, Marie Therese
    Xu, Judith
    Morando, Juliane
    Mahuzier, Bruyere
    Chandraiah, Satish Mahadevaiah
    Socie, Gerard
    BLOOD, 2020, 136
  • [10] MANAGEMENT OF CORTICOSTEROIDS IN PATIENTS RECEIVING RUXOLITINIB TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: A POST HOC ANALYSIS FROM THE RANDOMIZED PHASE 3 REACH3 STUDY
    Kintsch, Emily
    Xue, Zhenyi
    Galvin, John
    Locatelli, Franco
    Zeiser, Robert
    Bhatt, Valkal
    BONE MARROW TRANSPLANTATION, 2024, 59 : 310 - 310
12345